RxSight Inc. witnessed a dramatic 34% drop in after-hours trading after announcing revisions to its 2025 revenue forecast, sparking concerns among investors. The company’s stock closed at $8.40, down from $12.79, highlighting the market’s reaction to the updated financial outlook.